Clinical events by cohort and IKZF1 status
| . | IKZF1 wild-type . | IKZF1-deleted . | ||
|---|---|---|---|---|
| . | N . | % . | N . | % . |
| Pre-TKI | ||||
| No. of patients | 29 | 100.0 | 55 | 100.0 |
| Relapses (deaths after relapse) | 7 (3) | 24.1 | 31 (19) | 56.4 |
| BM involvement | 7 | 25 | ||
| Isolated extramedullary | 0 | 6 | ||
| Deaths in CCR | 6 | 20.7 | 7 | 12.7 |
| Deaths after HSCT | 5 | 4 | ||
| EsPhALL overall | ||||
| No. of patients | 36 | 100.0 | 71 | 100.0 |
| Relapses (deaths after relapse) | 7 (3) | 19.4 | 15 (10) | 21.1 |
| BM involvement | 6 | 12 | ||
| Isolated extramedullary | 1 | 3 | ||
| Deaths in CCR | 2 | 5.6 | 11 | 15.5 |
| Deaths after HSCT | 2 | 8 | ||
| EsPhALL good-risk | ||||
| No. of patients | 20 | 100.0 | 43 | 100.0 |
| Relapses (deaths after relapse) | 2 (0) | 10.0 | 11 (7) | 25.6 |
| BM involvement | 1 | 8 | ||
| Isolated extramedullary | 1 | 3 | ||
| Deaths in CCR | 0 | 0.0 | 6 | 14.0 |
| Deaths after HSCT | 0 | 4 | ||
| EsPhALL poor-risk | ||||
| No. of patients | 16 | 100.0 | 28 | 100.0 |
| Relapses (deaths after relapse) | 5 (3) | 31.3 | 4 (3) | 14.3 |
| BM involvement | 5 | 4 | ||
| Isolated extramedullary | 0 | 0 | ||
| Deaths in CCR | 2 | 12.5 | 5 | 17.9 |
| Deaths after HSCT | 2 | 4 | ||
| . | IKZF1 wild-type . | IKZF1-deleted . | ||
|---|---|---|---|---|
| . | N . | % . | N . | % . |
| Pre-TKI | ||||
| No. of patients | 29 | 100.0 | 55 | 100.0 |
| Relapses (deaths after relapse) | 7 (3) | 24.1 | 31 (19) | 56.4 |
| BM involvement | 7 | 25 | ||
| Isolated extramedullary | 0 | 6 | ||
| Deaths in CCR | 6 | 20.7 | 7 | 12.7 |
| Deaths after HSCT | 5 | 4 | ||
| EsPhALL overall | ||||
| No. of patients | 36 | 100.0 | 71 | 100.0 |
| Relapses (deaths after relapse) | 7 (3) | 19.4 | 15 (10) | 21.1 |
| BM involvement | 6 | 12 | ||
| Isolated extramedullary | 1 | 3 | ||
| Deaths in CCR | 2 | 5.6 | 11 | 15.5 |
| Deaths after HSCT | 2 | 8 | ||
| EsPhALL good-risk | ||||
| No. of patients | 20 | 100.0 | 43 | 100.0 |
| Relapses (deaths after relapse) | 2 (0) | 10.0 | 11 (7) | 25.6 |
| BM involvement | 1 | 8 | ||
| Isolated extramedullary | 1 | 3 | ||
| Deaths in CCR | 0 | 0.0 | 6 | 14.0 |
| Deaths after HSCT | 0 | 4 | ||
| EsPhALL poor-risk | ||||
| No. of patients | 16 | 100.0 | 28 | 100.0 |
| Relapses (deaths after relapse) | 5 (3) | 31.3 | 4 (3) | 14.3 |
| BM involvement | 5 | 4 | ||
| Isolated extramedullary | 0 | 0 | ||
| Deaths in CCR | 2 | 12.5 | 5 | 17.9 |
| Deaths after HSCT | 2 | 4 | ||
No second malignant neoplasm was observed in the 2 cohorts. EsPhALL cases were stratified in good-risk or poor-risk, based on their early clinical response. Fifteen of 20 IKZF1 wild-type EsPhALL good-risk patients received imatinib: 1 relapsed in BM and testis and none died in CCR. Thirty-six of 43 IKZF1-deleted EsPhALL good-risk patients received imatinib: 8 suffered from a relapse (5 in BM and 3 isolated extramedullary) and 5 died in CCR (4 after HSCT in CR1).
BM, bone marrow; CCR, continuous complete remission.